Clinical Trial for the Safety and Efficacy of APRIL CAR-T Cells Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
Latest Information Update: 18 May 2022
At a glance
- Drugs APRIL chimeric antigen receptor-T cell therapy-Yake Biotechnology (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 03 May 2022 Planned End Date changed from 15 Jan 2027 to 20 Aug 2027.
- 03 May 2022 Planned primary completion date changed from 15 Jan 2024 to 20 Aug 2024.
- 03 May 2022 Status changed from not yet recruiting to recruiting.